-+ 0.00%
-+ 0.00%
-+ 0.00%

D. Boral Capital Maintains Buy on Immunic, Maintains $8 Price Target

Benzinga·01/07/2026 13:57:04
語音播報
D. Boral Capital analyst Jason Kolbert maintains Immunic (NASDAQ:IMUX) with a Buy and maintains $8 price target.